Sanofi $300 million to expand cooperation with a in the field of celiac drug research

Source: Biovalley, May 14, 2015, with the rapid development of biotechnology, cooperation has become an eternal theme in the industry Recently, Sanofi announced that it will continue to deepen its partnership with selecta biotechnology, which has been cooperating for three years Sanofi announced that it has reached a $300 million research agreement with selecta for the development of drugs to treat celiac disease The agreement includes a series of milestone bonuses and research grants The reason why selecta is so popular with Sanofi is a synthetic vaccine particle immunotherapy developed by the company As we all know, the immune system of human body is one of the most powerful weapons to resist external hazards However, sometimes some immune responses of the immune system will do great harm to the body The technology developed by selecta can block these harmful immune reactions CEO Werner cautreels compared the technology image to "negative vaccine" to emphasize the difference between this technology and traditional vaccine to activate immune response And this technology also let Sanofi see the hope of developing drugs to treat celiac disease Previously, the two sides have carried out extensive cooperation in food allergy, type 1 diabetes and other fields At present, the former is in the late stage of clinical research, and the company expects that the treatment will enter the market in 2016 At the same time, selecta also announced that it has established a partnership with genethon, a famous French gene therapy company Genethon hopes to use the SVP technology of selecta company to overcome the side effects often encountered in the development of gene therapy, so as to further promote the current gene therapy Encouraged by these two good news, Werner cautreels, CEO of selecta, said that in the future, the company will consider IPO to strengthen the company's team.